Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by EternalPonzion Feb 13, 2020 7:58pm

128 Views

Post# 30688687

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FYI - George W. Haywood - SCHEDULE 13G - February 13, 2020

If he has slowly repurchased at the huge discount we've had for the past month he can't possibly think he will get away with it. It could be tough to prove. He could have had a contact at IQVIA that tipped him. There is a myriad of possibilities. Maybe he needed to raise cash. In any event, it is highly unusual to bail so much of your position from a company so close to breaking out. The optics look very bad and an explanation needs to be provided. You forfeit your right to privacy in situations like this. Cheating cannot be tolerated.

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports